Exploring the Anti-Cancer Mechanism of Novel 3,4′-Substituted Diaryl Guanidinium Derivatives

Exploring the Anti-Cancer Mechanism of Novel 3,4′-Substituted Diaryl Guanidinium Derivatives

We previously identified a guanidinium-based lead compound that inhibited BRAF through a hypothetic type-III allosteric mechanism. Considering the pharmacophore identified in this lead compound (i.e., “lipophilic group”, “di-substituted guanidine”, “phenylguanidine polar end”), several modifications...

Full description

Bibliographic Details
Main Authors: Viola Previtali, Helene B. Mihigo, Rebecca Amet, Anthony M. McElligott, Daniela M. Zisterer, Isabel Rozas
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Pharmaceuticals
Subjects:
3,4′-bis-guanidino
3-amino-4′-guanidino
diphenyl ether
phenyl pyridyl ether
intramolecular hydrogen bond
cancer cell viability
Online Access:https://www.mdpi.com/1424-8247/13/12/485

Internet

https://www.mdpi.com/1424-8247/13/12/485

Similar Items